Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis

Metabolism: Clinical and Experimental

Volumn 58, Issue 4, 2009, Pages 560-567

  Pamir, Nathalie ^a   McMillen, Timothy S ^a   Li, Yu I ^a   Lai, Ching Mei ^b   Wong, Howard ^b   LeBoeuf, Renée C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; CHOLESTEROL; GLUCOSE; INSULIN; LIPOPROTEIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; APOLIPOPROTEINS; BLOOD GLUCOSE; BODY WEIGHT; FEMALE; HOMEOSTASIS; INSULIN RESISTANCE; LIPASE; LIPIDS; MALE; MICE; MICE, TRANSGENIC; WEIGHT GAIN;

EID: 62349138735     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.11.018     Document Type: Article

References (51)

1. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
2. Brunzell J.D., and Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 115 Suppl 8A (2003) 24S-28S
3. Fujimoto W.Y. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 108 Suppl 6A (2000) 9S-14S
4. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
5. Fruchart J.C., Nierman M.C., Stroes E.S., Kastelein J.J., and Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 109 (2004) III15-III19
6. Banks W.A., Coon A.B., Robinson S.M., Moinuddin A., Shultz J.M., Nakaoke R., et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53 (2004) 1253-1260
7. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
8. van der Vliet H.N., Sammels M.G., Leegwater A.C., Levels J.H., Reitsma P.H., Boers W., et al. Apolipoprotein A-V: a novel apolipoproteins associated with an early phase of liver regeneration. J Biol Chem 276 (2001) 44512-44521
9. Fruchart-Najib J., Bauge E., Niculescu L.S., Pham T., Thomas B., Rommens C., et al. Mechanism of triglyceride lowering in mice expressing human apolipoproteins A5. Biochem Biophys Res Commmun 319 (2004) 397-404
10. Austin M.A., Talmud P.J., Farin F.M., Nicherson D.A., Edwards K.L., Leonetti D., et al. Association of apolipoproteins A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochem Biophys Acta 1688 (2004) 1-9
11. Horinek A., Vrablik M., Ceska R., Adamkova V., Poledne R., and Hubacek J.A. T1131→C polymorphism within the apolipoprotein A5 gene in hypertriglyceridemic individuals. Atherosclerosis 167 (2003) 369-370
12. Hubacek J.A., Skodova Z., Adamkova V., Lanska V., and Poledne R. The influence of APOA5 polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 65 (2004) 126-130
13. Lai C.Q., Tai E.S., Tan C.E., Cutter J., Chew S.K., Zhu Y.P., et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 44 (2003) 2365-2373
14. Mar R., Pajukanta P., Allayee H., Groenendijk M., Dallinga-Thie G., Krauss R.M., et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 94 (2004) 993-999
15. Olivier M., Wang X., Cole R., Gau B., Kim J., Ruben E.M., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83 (2004) 912-923
16. Grosskopf I., Baroukh N., Lee S.J., Kamari Y., Harats D., Rubin E.M., et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 25 (2005) 2573-2579
17. Merkel M., Loeffler B., Kluger M., Fabig N., Geppert G., Pennacchio L.A., et al. Apolipoprotein A5 accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycans-bound lipoprotein lipase. J Biol Chem 280 (2005) 21553-21560
18. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., van der Vliet H.N., Chamuleau R.A., et al. ApoA5 reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279 (2004) 27941-27947
19. Priore Oliva C., Pisciotta L., Li Volti G., Sambataro M.P., Cantafora A., Bellocchio A., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005) 411-417
20. Weinberg R.B., Cook V.R., Beckstead J.A., Martin D.D., Gallagher J.W., Shelness G.S., et al. Structure and interracial properties of human apolipoproteins A-V. J Biol Chem 278 (2003) 34438-34444
21. Schreyer S.A., Vick C., Lystig T.C., Mystkowski P., and LeBoeuf R.C. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes n mice. Am J Physiol Endocrinol Metab 282 (2002) E207-E214
22. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., and Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37 (1988) 1163-1167
23. Surwit R.S., Seldin M.F., Kuhn C.M., Cochrane C., and Feinglos M.N. Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL/6J mice. Diabetes 40 (1991) 82-87
24. Schreyer S.A., Cummings D.E., McKnight G.S., and LeBoeuf R.C. Mutation of the RIIbeta subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice. Diabetes 50 (2001) 2555-2562
25. Veronique Briquet-Laugier O.B.Z., and Doolittle M.H. Determining lipoprotein lipase and hepatic lipase activity using radiolabeled substrates (1998), Humana Press Inc, Totawa (NJ)
26. Noguchi T., and Tanaka T. Insulin resistance in obesity and its molecular control. Obes Res 3 Suppl 2 (1995) 195S-198S
27. Petro A.E., Cotter J., Cooper D.A., Peters J.C., Surwit S.J., and Surwit R.S. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53 (2004) 454-457
28. Zammit V.A., Waterman I.J., Topping D., and McKay G. Insulin stimulation of hepatic triacylglycerol secretion and the etiology of insulin resistance. J Nutr 131 (2001) 2074-2077
29. Baroukh N., Bauge E., Akiyama J., Chang J., Afzal V., Fruchart J.C., et al. Analysis of apolipoproteins A5, C3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 24 (2004) 1297-1302
30. Martin S., Nicaud V., Humphries S.E., and Talmud P.J. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 1637 (2003) 217-225
31. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 106 (2000) 453-458
32. Brunzell J.D., Hazzard W.R., Porte Jr. D., and Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52 (1973) 1578-1585
33. Chan D.C., Barrett P.H., and Watts G.F. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 17 (2006) 28-36
34. Duez H., Lamarche B., Uffelman K.D., Valero R., Cohn J.S., and Lewis G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 26 (2006) 1357-1363
35. Olano-Martin E., Abraham E.C., Gill-Garrison R., Valdes A.M., Grimaldi K., Tang F., et al. Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender. J Lipid Res 49 (2008) 945-953
36. Hubacek J.A., Skodová Z., Adámková V., Lánská V., and Poledne R. Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol. Metabolism 54 (2005) 1632-1635
37. Hubacek J.A., Lánská V., Skodová Z., Adámková V., and Poledne R. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur J Hum Genet 16 (2008) 135-138
38. Corella D., Chao-Qiang L., Demissie S., Cupples L.A., Manning A.K., Tucker K.L., et al. APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study. J Mol Med 85 (2007) 119-128
39. Lai C.Q., Corella D., Demissie S., Cupples L.A., Adiconis X., Zhu Y., et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size. The Framingham Heart Study. Circulation 113 (2006) 2062-2070
40. Harris R.B., Bowen H.M., and Mitchell T.D. Leptin resistance in mice is determined by gender and duration of exposure to high-fat diet. Physiol Behav 78 (2003) 543-555
41. Leiter E.H. The genetics of diabetes susceptibility in mice. FASEB J 3 (1989) 2231-2241
42. Nishikawa S., Yasoshima A., Doi K., Nakayama H., and Uetsuka K. Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. Exp Anim 56 (2007) 263-272
43. Costet P., Lagendre C., More J., Edgar A., Galtier P., and Pneau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273 (1998) 29577-29585
44. Tiraby C., TA5ernier G., Capel F., Mairal A., Crampes F., Rami J., et al. Resistance to high-fat-diet-induced obesity and sexual dimorphism in the metabolic responses of transgenic mice with moderate uncoupling protein 3 overexpression in glycolytic skeletal muscles. Diabetologia 50 (2007) 2190-2199
45. Zammaretti F., Panzica G., and Eva C. Sex-dependent regulation of hypothalamic neuropeptide Y-Y1 receptor gene expression in moderate/high-fat, high-energy diet-fed mice. J Physiol 583 (2007) 445-454
46. Morton G.J., Blevins J.E., Williams D.L., Niswender K.D., Gelling R.W., Rhodes C.J., et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest 115 (2005) 703-710
47. Morton G.J., Gelling R.W., Niswender K.D., Morrison C.D., Rhodes C.J., and Schwartz M.W. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2 (2005) 411-420
48. Willi S.M., Kennedy A., Wallace P., Ganaway E., Rogers N.L., and Garvey W.T. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51 (2002) 2895-2902
49. Hernandez J.P., Chapman L.M., Kretschmer X.C., and Baldwin W.S. Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice. Toxicol Appl Pharmacol 216 (2006) 186-196
50. Park S.H., Liu X., Hennighausen L., Davey H.W., and Waxman D.J. Distinctive role of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem 274 (1999) 7421-7430
51. Wang S., Yehya N., Schadt E.E., Wang H., Drake T.A., and Lusis A.J. Genetic and genomic analysis of a fat mass trait with complex inheritance reveals marked sex specificity. PLoS Genet 2 (2006) e15